AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29715698
Drug: 1,25‐(OH) 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25‐(OH) 2 D 3 (1 ng/mL)
Trial: 26813210
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch only (n=241)
Trial: 26813210
Drug: Combination nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination nicotine replacement therapy (C‐NRT) (n=421)
Trial: 22684521
Drug: HPV16 synthetic
RxNorm normalized name: Camphor (synthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 synthetic long-peptide vaccine (1-2 vaccinations)
Trial: 20711437
Drug: Multisensory exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory exercises (GMS), twice a week for 12 weeks
Trial: 20711437
Drug: Strength exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength exercises (GST), twice a week for 12 weeks
Trial: 17940245
Drug: Diazepam infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam infusion
Trial: 17198918
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 1.5 mg
Trial: 10628626
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg)
Trial: 8953340
Drug: Oral vanadyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vanadyl sulfate (VOSO4) 0.5 mg/kg/day
Trial: 8953340
Drug: Oral vanadyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vanadyl sulfate (VOSO4)
Trial: 6812154
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 35% CO2 mixture
Trial: 6812154
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of air (placebo control)
Trial: 29143550
Drug: Inebilizumab (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inebilizumab (IV doses: 30, 100, or 600 mg; SC doses: 60 or 300 mg)
Trial: 29143550
Drug: Inebilizumab (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inebilizumab (IV doses)
Trial: 29143550
Drug: Inebilizumab (SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inebilizumab (SC doses)
Trial: 21094099
Drug: Lignocaine gel-soaked
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine gel-soaked Falope rings
Trial: 21094099
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac suppository
Trial: 21094099
Drug: Conventional analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesic
Trial: 9260731
Drug: Sabeluzole 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabeluzole 5 mg twice daily
Trial: 9260731
Drug: Sabeluzole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabeluzole 10 mg twice daily
Trial: 9260731
Drug: Sabeluzole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabeluzole (5 or 10 mg)
Trial: 1437338
Drug: Exosurf (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosurf (3 doses)
Trial: 1437338
Drug: Exosurf (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosurf (2 doses)
Trial: 1437338
Drug: Exosurf (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosurf (1 dose)
Trial: 3873877
Drug: Betamethasone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (50 micrograms, total 300 micrograms) administered intradermally (i.d.) over 10 days
Trial: 3873877
Drug: Single i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.d. injection of 50 micrograms betamethasone 24 hours prior to anti-IgE challenge
Trial: 3873877
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of betamethasone 2 hours prior to and together with anti-IgE
Trial: 3873877
Drug: Betamethasone administered
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone administered i.d. 30 minutes following anti-IgE challenge
Trial: 26510505
Drug: Early chemotherapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early chemotherapy with docetaxel in addition to androgen deprivation therapy (ADT)
Trial: 21940058
Drug: Intracoronary tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary tirofiban administration (10 μg/kg)
Trial: 21940058
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control (10 mL)
Trial: 20658155
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate (15 mg b.d. for 14 days)
Trial: 18327671
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor exemestane alone
Trial: 18327671
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor exemestane in combination with antiestrogen tamoxifen
Trial: 12800412
Drug: Half-dose Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose Fenofibrate plus Taizhi'an
Trial: 12800412
Drug: Full-dose Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose Fenofibrate
Trial: 12800412
Drug: Half-dose Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose Simvastatin plus Taizhi'an
Trial: 12800412
Drug: Full-dose Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose Simvastatin
Trial: 8626839
Drug: Daily somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily somatropin treatment (0.3 mg/kg.week)
Trial: 7400374
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg plus reserpine 0.25 mg
Trial: 7400374
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg plus reserpine 0.125 mg
Trial: 30528307
Drug: B +
RxNorm normalized name: Vita b + C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B + O suppository
Trial: 24432622
Drug: Cardura 4
RxNorm normalized name: Cardura 4mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardura 4 mg qd for 8 weeks
Trial: 24432622
Drug: Cardura 4
RxNorm normalized name: Cardura 4mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardura 4 mg + Tolterodine L‐Tartrate Tablets 4 mg qd for 8 weeks
Trial: 21336952
Drug: Artificial gravity
RxNorm normalized name: SPECIFIC GRAVITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial gravity (AG) with ergometric exercise (40 W) for 30 min twice per day
Trial: 16988136
Drug: Multivitamin supplement
RxNorm normalized name: Vi-Daily Multivitamin Supplement Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplement containing folic acid (400 microg) with iron (18 mg)
Trial: 16988136
Drug: Multivitamin supplement
RxNorm normalized name: Vi-Daily Multivitamin Supplement Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplement containing folic acid (400 microg) without iron
Trial: 2188590
Drug: Amifloxacin 200
RxNorm normalized name: gatifloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 200 mg twice a day
Trial: 2188590
Drug: Amifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 400 mg twice a day
Trial: 7290416
Drug: Ribostamycin sulphate
RxNorm normalized name: Potassium sulphate
DrugBank: Ribostamycin (DB03615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribostamycin sulphate (1000‐2000 mg i.m.)
Trial: 7290416
Drug: Gentamycin (160‐240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamycin (160‐240 mg i.m.)
Trial: 7290416
Drug: Sodium cephalotin
RxNorm normalized name: Cephalothin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cephalotin (4‐8 g i.v.)
Trial: 26628607
Drug: Milnacipran 50
RxNorm normalized name: milnacipran 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 50 mg twice daily for 6 weeks
Trial: 26628607
Drug: Milnacipran 50
RxNorm normalized name: milnacipran 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 50 mg twice daily for 6 weeks (subgroup with swollen joint count ≤ 1)
Trial: 26552348
Drug: 14-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day standard regimen of triple therapy for peptic ulcer: omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, twice per day
Trial: 18308147
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with anthracyclines and taxanes
Trial: 18308147
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies (eg, trastuzumab and lapatinib)
Trial: 10626563
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at a total dose of 6 IU/m2/day (0.067 mg/kg/day) and ethinyloestradiol at a dose of 0.05 μg/kg/day
Trial: 10626563
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at a dose of 4 IU/m2/day (0.045 mg/kg/day) for group A, switched to 6 IU/m2/day for group B, and switched to 8 IU/m2/day for group C
Trial: 1685942
Drug: Epanolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epanolol (200 mg once daily)
Trial: 7036150
Drug: Vaccine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (5 microgram HBsAg per 1ml dose, 3 subcutaneous doses at one-month intervals)
Trial: 7036150
Drug: Vaccine (V)
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (V)
Trial: 27190374
Drug: Two high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two high flux dialyzers in parallel (blood flow ≥350 mL/min, dialysate flow 800 mL/min)
Trial: 27190374
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis using one high flux dialyzer (blood flow ≥350 mL/min, dialysate flow of 800 mL/min)
Trial: 25684674
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment with antispasmodics or antidiarrhoeal drugs (Group C)
Trial: 24252596
Drug: Aerobic interval
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic interval training (AIT) at 85-90% of VO2peak, 3 times weekly for 12 weeks, followed by 2 times weekly for 40 weeks
Trial: 24252596
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy diet (800-1000 kcal/day) for 12 weeks followed by weight maintenance combined with supervised AIT twice weekly for 40 weeks
Trial: 19477398
Drug: Carvedilol IR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol IR twice daily (BID)
Trial: 19477398
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR once daily (QD)
Trial: 30932889
Drug: Composite Supplement
RxNorm normalized name: DRESSING,COMPOSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Supplement Containing Astaxanthin and Sesamin
Trial: 30165840
Drug: Negative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative group (no treatment)
Trial: 10829585
Drug: Calcium-antagonists (non
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-antagonists (non dihydropyridinic compounds)
Trial: 10829585
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment or placebo)
Trial: 1414968
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg beta-carotene/d
Trial: 4003667
Drug: Metrifonate treatment
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate treatment (MIT, n = 202)
Trial: 28204953
Drug: Aln-NEF alone
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aln-NEF alone (70 mg)
Trial: 28204953
Drug: LT4 alone
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 alone (600 μg)
Trial: 19497149
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg pre-pregnancy body weight)
Trial: 19497149
Drug: Placebo (gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gelatin capsule)
Trial: 16988210
Drug: Desmopressin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin administered as an oral lyophilisate dosage form; specific dosage and duration not mentioned.
Trial: 16988210
Drug: Desmopressin in
RxNorm normalized name: desmopressin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin in children with nocturnal enuresis; specific dosage and duration not mentioned.
Trial: 16988210
Drug: Desmopressin in
RxNorm normalized name: desmopressin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin in healthy adults; specific dosage and duration not mentioned.
Trial: 15531011
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart injected immediately before the meal
Trial: 15531011
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart injected immediately after the meal
Trial: 11309011
Drug: 1.0% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% ropivacaine with 50 IU/ml hyaluronidase
Trial: 11309011
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine with 50 IU/ml hyaluronidase
Trial: 7936311
Drug: deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deprenyl (10 mg/d)
Trial: 5472805
Drug: Pre-exercise inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise inhalation of disodium cromoglycate
Trial: 21292872
Drug: Treatment post-infection
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment post-infection
Trial: 16303216
Drug: 4th booster
RxNorm normalized name: CEPHALOSPORIN 4TH GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4th booster dose of Hib
Trial: 12531776
Drug: Once-weekly isoniazid/rifapentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly isoniazid/rifapentine
Trial: 12531776
Drug: Control cases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cases (not specified but implied to be twice-weekly isoniazid/rifampin)
Trial: 12531776
Drug: Twice-weekly isoniazid/rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly isoniazid/rifampin
Trial: 2851016
Drug: Enoxaparine 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparine 20 mg
Trial: 2851016
Drug: Enoxaparine 40
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparine 40 mg
Trial: 3344486
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with plain bupivacaine for 48 hours and epidural morphine 4 mg every 8 hours for 96 hours plus systemic indomethacin 100 mg every 8 hours for 96 hours
Trial: 3344486
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative pain treatment with intermittent nicomorphine (10 to 15 mg) and acetaminophen (1 gm) on request
Trial: 27287781
Drug: Atorvastatin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin at 10, 20, or 40 mg/day for 3 months
Trial: 23701177
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) 0.7 mg daily for 40 weeks
Trial: 3074463
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg orally b.i.d. for seven days
Trial: 3074463
Drug: Co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) orally b.i.d. for seven days
Trial: 23333902
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg vs 80 mg
Trial: 21540876
Drug: 20% blackcurrant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% blackcurrant juice drink (250 ml)
Trial: 19417960
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% levobupivacaine
Trial: 19417960
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% bupivacaine
Trial: 17558046
Drug: Niosomal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Niosomal methotrexate gel
Trial: 17558046
Drug: Marketed methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Marketed methotrexate gel
Trial: 11851027
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 (n = 28)
Trial: 11851027
Drug: Methylprednisolone 1
RxNorm normalized name: methylprednisolone 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1 g (n = 21)
Trial: 9657119
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 6 MU rIFN-alpha plus 14 mg/kg ribavirin
Trial: 31042696
Drug: MDMA (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (0.75 or 1.5 mg/kg)
Trial: 31042696
Drug: MA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA (20 mg)
Trial: 20368377
Drug: Ayurvedic zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic zinc tablet (jasad bhasma)
Trial: 9692071
Drug: Fluoride (sodium
RxNorm normalized name: fluoride (sodium) 2.3 % DENTAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride (sodium fluoride 50 mg/day or monofluorophosphate 200 mg/day or 150 mg/day)
Trial: 9692071
Drug: Calcium-vitamin D
RxNorm normalized name: Calcium-Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D (1 g of calcium and 800 IU of vitamin D2 daily)
Trial: 8820898
Drug: Downhill running
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Downhill running at 2.0 mmol.l‐1 [La‐]b
Trial: 8820898
Drug: Level running
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level running at 2.0 mmol.l‐1 [La‐]b
Trial: 8820898
Drug: Uphill running
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uphill running at 2.0 mmol.l‐1 [La‐]b
Trial: 8820898
Drug: Treadmill speed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill speed at 4.0 mmol.l‐1 [La‐]b
Trial: 8820898
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of treadmill speed with RPE at 2.0 mmol.l‐1 [La‐]b
Trial: 2389831
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg/twice daily for 21 days)
Trial: 6273020
Drug: Cortisone acetate
RxNorm normalized name: Cortisone Acetate
DrugBank: Cortisone (DB14681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cortisone acetate (25 mg)
Trial: 25970751
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g bilberries daily for 7 days
Trial: 25970751
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g bilberries daily for 7 days
Trial: 25188752
Drug: ACCESS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCESS treatment model (integrated care including therapeutic assertive community treatment)
Trial: 18576295
Drug: Chicken type
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken type II collagen (CCII) 0.1 mg/day